SARS-CoV-2-specific ELISA development
Vicky Roy(Ragon Institute of MGH, MIT and Harvard), Galit Alter(Ragon Institute of MGH, MIT and Harvard), Tyler E. Miller(Case Comprehensive Cancer Center), Richelle C. Charles(Massachusetts General Hospital), Michael G. Astudillo(Massachusetts General Hospital), Corinne Luedemann(Ragon Institute of MGH, MIT and Harvard), Duane R. Wesemann(Brigham and Women's Hospital), Jared Feldman(Ragon Institute of MGH, MIT and Harvard), Edward T. Ryan(Harvard University), Blake M. Hauser(Ragon Institute of MGH, MIT and Harvard), Carolin Loos(International Council on Mining and Metals), Eric J. Nilles(Brigham and Women's Hospital), Caroline Atyeo(Ragon Institute of MGH, MIT and Harvard), A. John Lafrate(Massachusetts General Hospital), Douglas A. Lauffenburger(Harvard University), Stephanie Fischinger(Leiden University), Alejandro B. Balazs(Ragon Institute of MGH, MIT and Harvard), Matthew D. Slein(The University of Texas at Austin), Wilfredo Garcia Beltran(Massachusetts General Hospital), Lindsey R. Baden(Brigham and Women's Hospital), Diane Yang(Massachusetts General Hospital), Mandakolathur R. Murali(Massachusetts General Hospital), Timothy M. Caradonna(Ragon Institute of MGH, MIT and Harvard)
Cited by 97
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981